Ilkka Kantola
Professor; Head of Medical Division, Turku university Hospital
ilkkan@utu.fi ORCID identifier: https://orcid.org/0000-0002-6228-522X |
Areas of expertise
Hypertensio;Fabry disease; diabetes mellitus; sleep apnea
Hypertensio;Fabry disease; diabetes mellitus; sleep apnea
Publications
- Genetics, cardiac phenotype and cardiovascular outcomes in Fabry disease patients in Finland (2025)
- ESC Heart Failure
(A1 Refereed original research article in a scientific journal) - Clinical outcomes in patients switching from agalsidase beta to migalastat : A Fabry Registry analysis (2024)
- Journal of Inherited Metabolic Disease
(A1 Refereed original research article in a scientific journal) - Hemodynamic Bedside Monitoring Instrument with Pressure and Optical Sensors : Validation and Modality Comparison (2024)
- Advanced Science
(A1 Refereed original research article in a scientific journal) - Hypertensio: primaarinen hypertensio (2024) Kardiologia Kantola, Ilkka; Niiranen, Teemu
(D2 Article in a professional compilation book) - Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney (2024)
- Blood Pressure
(A1 Refereed original research article in a scientific journal) - Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire (2024)
- Journal of Hypertension
(A1 Refereed original research article in a scientific journal) - Verenpainetaudin lääkehoito yksilöllistyy (2024)
- Lääkärilehti
(A2 Refereed review article in a scientific journal ) - An expert consensus on the recommendations for the use of biomarkers in Fabry disease (2023)
- Molecular Genetics and Metabolism
(A2 Refereed review article in a scientific journal ) - Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF) (2023)
- Primary Care Diabetes
(A1 Refereed original research article in a scientific journal) - Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry (2023)
- Molecular Genetics and Metabolism
(A1 Refereed original research article in a scientific journal)



